((Jamie Lee, PharmD))
Granulocyte-colony stimulating factor may be needed when treating a patient with VYXEOS.
Count recovery may be prolonged approximately 6 more days with VYXEOS than with 7+3.
The conditions dictating when this is given will vary based on the individual patient’s response to therapy, and we continuously monitor the patient’s absolute neutrophil count to determine if and when they need may need granulocyte-colony stimulating factor.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION